Hepatotoxicity of chemotherapeutic agents such as methotrexate, oxaliplatin, and irinotecan
have been well documented and characterized allowing for careful management by …

Since the discovery of targeted therapy with epidermal growth factor receptor (EGFR),
anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been introduced as …

Purpose Crizotinib is the first-line small molecule tyrosine kinase inhibitor for ALK-positive
non-small cell lung cancer. In this study, a retrospective pharmacogenomics investigation …

Abstract c-Met inhibitors are a class of drugs that include nonselective and selective
molecules. These drugs can differ in terms of pharmacodynamic and pharmacokinetic …

Methods A comprehensive search of related articles was performed focused on phases Ⅱ
and Ⅲ clinical trials studies. Results The lung cancer management should take into …

ABSTRACT Introduction: As of October 2019, the US Food and Drug Administration (FDA)
has approved 53 small molecule kinase inhibitors (KI), which account for about 10% of all …

Irinotecaninduced hepatotoxicity can cause severe clinical complications in patients;
however, the underlying mechanism and factors affecting hepatotoxicity have rarely been …

Purpose Although several studies have examined tyrosine kinase inhibitor (TKI)-induced
hepatotoxicity, the majority of patients in those studies displayed low-grade (grade I–II) …

What is known and Objective. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors (ALK
TKIs) are standard firstline therapy for nonsmall cell lung cancer patients with ALK …

Crizotinib is a firstline tyrosine kinase inhibitor used for the treatment of metastatic lung
cancer. Crizotinibinduced hepatotoxicity is a rare event. We report a case of a 46yearold …